More precisely, the study showed that the CAR-NK cells (NK92/5.28.z cells) were significantly improved in their therapeutic efficacy when combined with an anti-PD-1 antibody, resulting in the successful treatment of advanced tumours that were resistant to NK92/5.28.z monotherapy. Here, PDCD1 is linked to neoplasm.